Cargando…
Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study
OBJECTIVES: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590155/ https://www.ncbi.nlm.nih.gov/pubmed/30620136 http://dx.doi.org/10.1111/hiv.12699 |
_version_ | 1783429496837242880 |
---|---|
author | Costiniuk, CT Nitulescu, R Saneei, Z Wasef, N Salahuddin, S Wasef, D Young, J de Castro, C Routy, JP Lebouché, B Cox, J Smith, BM Ambroise, S Pexos, C Patel, M Szabo, J Haraoui, LP de Pokomandy, A Tsoukas, C Falutz, J LeBlanc, R Giannakis, A Frenette, C Jenabian, MA Bourbeau, J Klein, MB |
author_facet | Costiniuk, CT Nitulescu, R Saneei, Z Wasef, N Salahuddin, S Wasef, D Young, J de Castro, C Routy, JP Lebouché, B Cox, J Smith, BM Ambroise, S Pexos, C Patel, M Szabo, J Haraoui, LP de Pokomandy, A Tsoukas, C Falutz, J LeBlanc, R Giannakis, A Frenette, C Jenabian, MA Bourbeau, J Klein, MB |
author_sort | Costiniuk, CT |
collection | PubMed |
description | OBJECTIVES: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible airflow obstruction in order to guide case finding strategies for COPD. METHODS: All adults attending the Chronic Viral Illness Service were invited to participate in the study, regardless of smoking status or history of known COPD/asthma. Individuals underwent spirometric testing both before and after use of a salbutamol bronchodilator. Airflow obstruction was defined as forced expiratory volume in 1 s (FEV (1))/forced vital capacity (FVC) < 0.7 post‐bronchodilation, whereas COPD was defined as FEV (1)/FVC < 0.7 post‐bronchodilation and Medical Research Council (MRC) score > 2. Multivariate logistic regression was used to evaluate risk factors associated with airflow obstruction, reported as adjusted odds ratios (aORs). RESULTS: Five hundred and three participants successfully completed spirometry testing. The median (Q1; Q3) age was 52 (44; 58) years. The median (Q1; Q3) CD4 count was 598 (438; 784) cells/μL and the median (Q1; Q3) nadir CD4 count was 224 (121; 351) cells/μL. There were 119 (24%) current smokers and 145 (29%) former smokers. Among those screened, 54 (11%) had airflow obstruction whereas three (1%) of the participants had COPD. Factors that were associated with airflow obstruction included a history of smoking [aOR 2.2; 95% confidence interval (CI) 1.1; 4.7], older age (aOR 1.6; 95% CI 1.2; 2.2), and lower CD4 count (aOR 0.8; 95% CI 0.7; 1.0). CONCLUSIONS: Airflow obstruction was relatively uncommon. Our findings suggest that PLWHIV who are ≥50 years old, smokers and those with nadir CD4 counts ≤ 200 cells/μL could be targeted to undergo spirometry to diagnose chronic airflow obstruction. |
format | Online Article Text |
id | pubmed-6590155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65901552019-07-08 Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study Costiniuk, CT Nitulescu, R Saneei, Z Wasef, N Salahuddin, S Wasef, D Young, J de Castro, C Routy, JP Lebouché, B Cox, J Smith, BM Ambroise, S Pexos, C Patel, M Szabo, J Haraoui, LP de Pokomandy, A Tsoukas, C Falutz, J LeBlanc, R Giannakis, A Frenette, C Jenabian, MA Bourbeau, J Klein, MB HIV Med Original Research OBJECTIVES: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible airflow obstruction in order to guide case finding strategies for COPD. METHODS: All adults attending the Chronic Viral Illness Service were invited to participate in the study, regardless of smoking status or history of known COPD/asthma. Individuals underwent spirometric testing both before and after use of a salbutamol bronchodilator. Airflow obstruction was defined as forced expiratory volume in 1 s (FEV (1))/forced vital capacity (FVC) < 0.7 post‐bronchodilation, whereas COPD was defined as FEV (1)/FVC < 0.7 post‐bronchodilation and Medical Research Council (MRC) score > 2. Multivariate logistic regression was used to evaluate risk factors associated with airflow obstruction, reported as adjusted odds ratios (aORs). RESULTS: Five hundred and three participants successfully completed spirometry testing. The median (Q1; Q3) age was 52 (44; 58) years. The median (Q1; Q3) CD4 count was 598 (438; 784) cells/μL and the median (Q1; Q3) nadir CD4 count was 224 (121; 351) cells/μL. There were 119 (24%) current smokers and 145 (29%) former smokers. Among those screened, 54 (11%) had airflow obstruction whereas three (1%) of the participants had COPD. Factors that were associated with airflow obstruction included a history of smoking [aOR 2.2; 95% confidence interval (CI) 1.1; 4.7], older age (aOR 1.6; 95% CI 1.2; 2.2), and lower CD4 count (aOR 0.8; 95% CI 0.7; 1.0). CONCLUSIONS: Airflow obstruction was relatively uncommon. Our findings suggest that PLWHIV who are ≥50 years old, smokers and those with nadir CD4 counts ≤ 200 cells/μL could be targeted to undergo spirometry to diagnose chronic airflow obstruction. John Wiley and Sons Inc. 2019-01-08 2019-03 /pmc/articles/PMC6590155/ /pubmed/30620136 http://dx.doi.org/10.1111/hiv.12699 Text en © 2019 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Costiniuk, CT Nitulescu, R Saneei, Z Wasef, N Salahuddin, S Wasef, D Young, J de Castro, C Routy, JP Lebouché, B Cox, J Smith, BM Ambroise, S Pexos, C Patel, M Szabo, J Haraoui, LP de Pokomandy, A Tsoukas, C Falutz, J LeBlanc, R Giannakis, A Frenette, C Jenabian, MA Bourbeau, J Klein, MB Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study |
title | Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study |
title_full | Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study |
title_fullStr | Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study |
title_full_unstemmed | Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study |
title_short | Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross‐sectional study |
title_sort | prevalence and predictors of airflow obstruction in an hiv tertiary care clinic in montreal, canada: a cross‐sectional study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590155/ https://www.ncbi.nlm.nih.gov/pubmed/30620136 http://dx.doi.org/10.1111/hiv.12699 |
work_keys_str_mv | AT costiniukct prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT nitulescur prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT saneeiz prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT wasefn prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT salahuddins prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT wasefd prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT youngj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT decastroc prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT routyjp prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT leboucheb prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT coxj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT smithbm prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT ambroises prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT pexosc prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT patelm prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT szaboj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT haraouilp prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT depokomandya prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT tsoukasc prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT falutzj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT leblancr prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT giannakisa prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT frenettec prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT jenabianma prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT bourbeauj prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy AT kleinmb prevalenceandpredictorsofairflowobstructioninanhivtertiarycareclinicinmontrealcanadaacrosssectionalstudy |